Company Overview
Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to translating advanced cell therapies into potential cures for difficult-to-treat cancers and autoimmune diseases within the United States. The company functions within the Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at bringing novel therapeutic agents to market. As of the latest available data, the company maintains a market capitalization of $5.48M and employs a workforce of 4 individuals, while its annual revenue and price-to-sales metrics are not currently disclosed. This combination of a small market cap and the absence of reported revenue figures indicates that the company is in an early-stage development phase where value is primarily derived from intellectual property and pipeline potential rather than commercial product sales.
Financial Health
The company reported a net income of $-1,921,000 and an EBITDA of $-2,398,000 over the trailing twelve months, while annual revenue data is not available for reporting. The significant gap between the reported net income loss and the EBITDA loss reveals a substantial cost structure burdened by non-cash expenses such as stock-based compensation or amortization of intangible assets that are standard in early-stage biotechnology firms. Mustang Bio, Inc. generated a free cash flow of $-4,149,000, which signifies a heavy cash burn rate typical for clinical-stage entities undergoing Phase I trials and necessitates continuous capital infusion to sustain operations. The company's profitability metrics reflect a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, indicating that the company is not yet generating profit from its sales or operations due to the absence of commercial revenue. On the liquidity front, the company holds $17.27M in cash against a debt level that is not applicable, resulting in a debt-to-equity ratio that is not applicable. The balance sheet is currently un-leveraged, relying entirely on cash reserves to fund its developmental activities rather than utilizing debt financing. Furthermore, the current ratio stands at 2.22, suggesting that the company possesses more than double the current assets needed to cover its short-term liabilities, thereby indicating a strong position regarding immediate solvency despite the cash burn. Return on Equity is recorded at -67.9% and Return on Assets at -11.3%, metrics that reveal management is currently allocating capital to generate losses rather than positive returns, a characteristic expected for companies prioritizing research and development over immediate profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -2.07, implying that the market anticipates continued negative earnings growth in the near term. The price-to-book ratio is 0.55, indicating that the stock trades at a significant discount to its book value, which often occurs when investors price in high uncertainty regarding the commercial viability of the company's pipeline. The price-to-sales ratio is not available, and the EV/EBITDA stands at 4.92, suggesting that valuation multiples are heavily compressed relative to traditional metrics due to the lack of positive earnings and sales data. Regarding trading range, the stock has a 52-week high of $7.00 and a 52-week low of $0.53, meaning the current trading price sits within this established volatility band but the specific percentage below the high requires the current price which is not explicitly stated in the provided facts. The beta value is 2.15, which indicates that the stock price is significantly more volatile than the broader market, moving with an amplitude roughly twice that of the overall index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available for reporting, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this stage. Since the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, indicating that the company reinvests all available earnings and cash flow back into its research and development operations rather than distributing income to shareholders. The overall growth and income profile is characterized by an absence of historical growth metrics and no current income generation, reflecting the typical trajectory of a clinical-stage biopharmaceutical company focused on pipeline advancement. The company's financial strategy relies on retaining capital to advance its Phase I therapies rather than providing a dividend yield to investors.